New blood test could be a game changer for those living with Alzheimer's disease
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
The Fresh Market Donates More Than $21,000 in Support of the Alzheimer's Association
GREENSBORO, N.C.--(BUSINESS WIRE)--The Fresh Market is proud to announce it has donated more than $21,000 in collaboration with celebrity chef Carla Hall to support the Alzheimer's Association. Throughout the month of June, the premium grocery retailer pledged to donate 10 percent of the sales price of Carla Hall's Sweet Heritage Butter Tarts to the Alzheimer's Association. Throughout the month of June, the premium grocery retailer pledged to donate 10 percent of the sales price of Carla Hall's Sweet Heritage Butter Tarts to the Alzheimer's Association. The campaign aimed to raise awareness and fund critical research toward a cure. In total, The Fresh Market contributed $21,541.70 to the organization. 'It was our pleasure to partner with Carla Hall to help raise awareness and support for the millions of Americans living with Alzheimer's disease,' said Emily Turner, chief marketing officer at The Fresh Market. 'This cause is close to our hearts at The Fresh Market, and we're incredibly grateful to the Alzheimer's Association, Carla Hall, and—most importantly—our guests for helping us reach our fundraising goals.' 'We're grateful to The Fresh Market and Carla Hall for their commitment to the fight to end Alzheimer's and all other dementia,' said Sarah Fried, vice president, corporate initiatives, Alzheimer's Association. 'Alzheimer's impacts millions of families and partnerships like this help fund critical care and support services and disease research, while spurring important conversation and encouraging others to join us in the fight to end this disease.' Carla Hall—known for her appearances on Bravo, Food Network, and ABC —is a passionate advocate for individuals living with Alzheimer's disease and a longtime supporter of the Alzheimer's Association. Her advocacy is deeply personal, inspired by her grandmother's experience with the disease. 'A big ol' thank you to everyone who stopped by The Fresh Market and picked up my Sweet Heritage Butter Tarts!' said Carla Hall. 'Y'all didn't just treat yourselves — you helped raise more than $21,000 for the Alzheimer's Association! 'That's a whole lot of goodness doing double duty: satisfying your sweet tooth and supporting critical research to help us get closer to a cure. I'm so proud to be part of this delicious way to give back. Let's keep showing up for each other and keep working to #ENDALZ — one bite at a time!' The number of Americans living with Alzheimer's is growing — and growing fast. According to the Alzheimer's Association's 2025 Facts and Figures report, nearly 7 million Americans are living with Alzheimer's and it is estimated that more than half of all Americans know someone with the disease. Additionally, almost 12 million family members and friends serve as dementia caregivers. About The Fresh Market Rated by USA Today as one of America's Best Customer Service Companies in 2025, voted #1 in three categories by USA Today's 10Best Readers' Choice Awards for 2024—"Best Grocery Store Bakery," "Best Grocery Store Deli," and "Best Grocery Store Prepared Foods"—and recognized for three consecutive years as the 'Best Grocery Store in America.' The Fresh Market currently operates more than 170 grocery stores in 22 states across the U.S. and one Spirits & Wine store, inspiring guests to discover new flavors and cook with confidence. For more information, please visit or follow the company on Facebook, Instagram, TikTok, X and Pinterest. About the Alzheimer's Association The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit or call 800.272.3900. About Carla Hall Chef, best-selling author and television personality Carla Hall has been entertaining audiences with her enthusiasm for life and warm personality for years. She has starred on Food Network shows such as 'BakeAway Camp,' 'Halloween Baking Championship,' 'Holiday Baking Championship' and 'Worst Cooks in America.' She also hosted the Emmy-nominated 'Chasing Flavor with Carla Hall' (HBO Max) and serves as a judge on 'Harry Potter: Wizards of Baking' (HBO Max). She first won over audiences when she competed on Bravo's 'Top Chef' and hosted ABC's 'The Chew' for 7 years. Her product line, Sweet Heritage by Carla Hall (available through QVC), is designed to bring you kitchen items that are useful, reliable, and complete with a dash of joy and soul. Carla's latest cookbook, Carla Hall's Soul Food: Everyday and Celebration, was published in 2018, landing on annual "Best Cookbook" lists across the country and receiving an NAACP Image Awards nomination. Her second children's book, Carla and the Tin Can Cake Party will be published October 14th.
Yahoo
3 hours ago
- Yahoo
A Single Brain Scan Halfway Through Your Life Can Reveal How Fast You're Aging
The rate at which our bodies age and wear down doesn't necessarily match our actual age, and the differences can help predict lifespan and disease risk. Now, researchers have developed a new tool for assessing biological age from a single brain scan taken halfway through our lives. The tool, put together by an international team of scientists, is based on a dataset of 1,037 people born in Dunedin in New Zealand in 1972 and 1973. The health of these individuals has been carefully tracked over time, giving scientists a useful long-term database of stats that reflect the body's actual age – not how many birthdays have passed. Here, the researchers used those stats to assess biological aging, and train a tool they've called DunedinPACNI – Pace of Aging Calculated from NeuroImaging. That sums up its function, which is to match aging to markers in the brain. Related: Dementia Breakthrough: Brain Scans Predict Disease Up to 9 Years Early The system has the potential to quickly assess the body's age to a good degree of accuracy, and from there health and disease risks, including the chances of dementia. Rather than needing multiple tests over time, just a single brain scan is required. "What's really cool about this is that we've captured how fast people are aging using data collected in midlife," says neuroscientist Ahmad Hariri from Duke University in North Carolina. "And it's helping us predict diagnosis of dementia among people who are much older." DunedinPACNI takes in 99 key brain measurements to make its assessment, including the thickness of the cerebral cortex – which affects language and thinking – and the volume of gray matter in the brain. Once the researchers had developed DunedinPACNI, they tested it on a variety of data from other health research projects, covering more than 50,000 people in total. It was shown to work well at estimating biological age, and at predicting future health problems such as cognitive impairment and heart attacks. It's not a tool that offers perfect accuracy each time, but it scores as well as or better than current biological age assessment methods, the researchers say. What's more, it was shown to be useful across different demographic and socioeconomic groups. "The link between aging of the brain and body is pretty compelling," says Hariri. "It seems to be capturing something that is reflected in all brains." If we know that someone's body is aging faster than their chronological age, it means measures can be taken to reduce the risk of health problems – years or even decades before those health problems might otherwise become evident. Changes in diet or exercise at that point could make a major difference. The researchers are particularly interested in predicting the risk of the various types of dementia, including Alzheimer's disease. As people live longer across the world, rates of dementia are increasing, and the best way to tackle the condition could be to stop it developing in the first place. "We really think of it as hopefully being a key new tool in forecasting and predicting risk for diseases, especially Alzheimer's and related dementias, and also perhaps gaining a better foothold on progression of disease," says Hariri. The research has been published in Nature Aging. Related News Surgeons Resuscitate 'Dead' Heart in Life-Saving Organ Transplant to Baby Huge Study Reveals 2 Vaccines That Appear to Reduce Dementia Risk One Dietary Supplement Shown to Reduce Aggression by Up to 28% Solve the daily Crossword
Hamilton Spectator
4 hours ago
- Hamilton Spectator
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease
CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PMN310, the Company's lead therapeutic candidate in development for the treatment of Alzheimer's disease (AD). The FDA Fast Track program is intended to accelerate the development of therapies that aim to address serious conditions and fill an unmet medical need. This designation enables enhanced engagement with the FDA, opening the door to a potentially more efficient path to approval for PMN310. 'This is a pivotal moment for ProMIS and the Alzheimer's community, as receiving Fast Track designation not only underscores the potential of PMN310 to address a critical unmet need, but also provides valuable opportunities for regulatory insight as we advance toward key clinical milestones,' said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. 'We designed PMN310 with a goal of providing Alzheimer's patients with a safer and more efficacious treatment option, which we believe represents the next generation of Alzheimer's therapeutics. By selectively targeting only the most harmful, toxic forms of amyloid-beta, we believe PMN310 has the potential to reduce the serious side effects seen with current Alzheimer's treatments, namely brain swelling and bleeding known as ARIA, while also delivering improved therapeutic benefit to patients.' The ongoing PRECISE-AD Phase 1b trial is evaluating PMN310 in patients with early AD. The study is focused on characterizing safety, tolerability, pharmacokinetics, and disease-relevant biomarkers. ProMIS anticipates reporting interim six-month biomarker and safety data in Q2 '26 and final results in Q4 '26. AD affects more than 6 million people in the U.S. and remains a leading cause of death and disability among older adults. Despite progress in the field, the need for safer, more targeted treatment options remains urgent. About PMN310 and the PRECISE-AD Trial for Alzheimer's Disease (AD) PMN310, the Company's lead product candidate for the treatment of AD, is a humanized monoclonal antibody that has been designed to be differentiated in its ability to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing or eliminating ARIA liability. In addition, because PMN310 may not be limited by off-target binding or side effects, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics. Based on the encouraging results from the Phase 1a trial ( NCT06105528 ) of PMN310, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD ( NCT06750432 ) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD). PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against AβO on biomarkers associated with AD pathology and clinical outcomes. Safety will be a primary outcome of the study with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. The study has been designed with a sample size intended to provide sufficient power to provide meaningful insight into effects of PMN310 on biomarkers and clinical outcomes. About ProMIS Neurosciences Inc. ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, predicts novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN). Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, 'forward-looking information') within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as 'plans', 'pleased to', 'look forward to', 'potential to', 'targets', 'expects' or 'does not expect', 'is expected', 'excited about', 'an opportunity exists', 'is positioned', 'estimates', 'intends', 'assumes', 'anticipates' or 'does not anticipate' or 'believes', or variations of such words and phrases or state that certain actions, events or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur' or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company's progress and expectations for its Phase 1b clinical trial in AD patients, including planned timing for completion and anticipated data readout of interim and full results, the potential for such studies to provide the first proof-of-concept data for PMN310, the potential that PMN310 has the potential to positively benefit patients with AD and to be a more effective and well-tolerated option, the targeting of toxic misfolded proteins in neurodegenerative diseases that the Company believes may directly address fundamental AD pathology (including the belief and understanding that toxic oligomers of Aβ are a major driver of AD) and have greater therapeutic potential due to reduction of off-target activity and the Company's expectations regarding the benefits of Fast Track Designation. Statements containing forward-looking information are not historical facts but instead represent management's current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that clinical results or early results may not be indicative of future results, the Company's ability to retain and recognize the incentives conferred by Fast Track Designation for PMN310, the Company's ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the 'Risk Factors' section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2024 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. For further information: Visit us at Please submit media inquiries to info@ For Investor Relations, please contact: Kaytee Bock Zafereo
